Clinical trial
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in…
NCT00240071 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00240071 |
|---|---|
| Title | Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca. |
| Official title | The Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Metastatic Breast Cancer Patients Previously Responsive to Hormonal Therapy: A Phase II Trial |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Avastin, Hormonal therapy |
| Enrollment | 30 |
| Start date | Oct 1, 2005 |
| Primary completion | Mar 1, 2009 |
| Completion | Apr 1, 2011 |
| First posted | Oct 17, 2005 |
| Last update posted | Oct 30, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: